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 Abstract
Objectives: Poly (ADP-ribose) polymerase (PARP-1) is involved in the processes of DNA repair, contributing to 
the maintenance of genomic stability. Recent data suggest that polymerase is involved in the development of 
endometrial adenocarcinomas and more advanced tumors displaying lowest enzyme protein expression. Data on 
PARP-1 activity regarding carcinogenesis in human endometrium are scarce. That was the reason why the authors 
of the present work wished to investigate the enzyme activity in human uterine hormone-dependent cancer and to 
compare the results with those obtained for normal endometrial tissue. The next aim was to check whether enzyme 
activity in normal and cancerous endometrium depends on the number of AP sites, which are widely known as 
oxidative stress DNA damage markers and PARP-1 activity stimulators.
Material and methods: Universal Colorimetric PARP Assay Kit was used to estimate the enzyme activity in units/
mg protein. Apurinic sites/105 base pairs (bp) were measured by Oxidative DNA Damage Kit Quantitative. Results 
were calculated for 47 endometrial samples and 15 uterine adenocarcinomas specimens. Finally, the PARP-1 
activity was analyzed for histological and some clinical features of neoplasms. 
Results and conclusions: 
1.  no differences in PARP-1 activity were found in non-cancerous types of human endometrium; 
2.  mean enzyme activity was lower in sporadic endometrial cancers than in noncancerous endometrial specimens 
 (2.89±0.55 vs 6.39±0.06; p<0.005);  
3.  mean PARP-1 activity in lower grade neoplasms was higher than in G3 tumors and was lower in adenocarcinomas 
 displaying deep uterine wall infiltration; 
4.  there was no relationship between PARP-1 activity and AP level. 
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Introduction
Poly	(ADP-ribose)	polymerase	(PARP,	ADPRP,	EC	2.4.2.30)	
is	a	nuclear	enzyme	which	becomes	activated	in	response	to	DNA	
damage,	 especially	 single-strand	breaks	 [1,	 2].	PARP	accounts	
for	about	90%	of	the	total	cellular	poly(ADP-ribose)	formation	
which	 is	 a	 post-translational	 protein	 modification	 involving	
the	transfer	of	ADP-ribose	groups	from	NAD+	to	more	than	30	
nuclear	acceptor	proteins,	including	histones	and	PARP	itself	[3,	
4].	 PARP-1	 enzyme,	which	 is	 the	 best	 studied	member	 of	 the	
PARP	protein	family	that	are	encoded	in	mammals	by	eighteen	
genes,	plays	the	primary	role	in	the	process	of	poly(ADP-ribosyl)
ation	[5,	6].	Experimental	studies	have	revealed	that	rapid	increase	
in	PARP	activity	 is	 strongly	 connected	 not	 only	with	 estrogen	
administration	 but	 also	 tissue	 proliferation,	 whereas	 prompt	
decrease	 in	 that	enzyme	activity	was	reported	 to	occur	 in	cells	
after	 treatment	with	pharmaceuticals	 that	 blocked	proliferation	
[7,	8,	9,	10].	
Bürkle	 et	 al.	 [11]	 suggest	 that	 higher	 activity	 of	 PARP	
protects	 against	 genome	 instability	 and	 probably	 is	 helpful	
in	 increasing	 cell	 longevity.	 Paradoxically,	 however,	 during	
inflammation,	ischemia-reperfusion,	or	shock,	over-activation	of	
PARP-1	leads	to	necrotic	cell	death,	because	poly(ADP-ribosyl)
ation	 reaction	 depletes	 cellular	 energy	 by	 overconsumption	 of	
NAD+	that	affects	the	size	of	the	cellular	NAD+	pool	[12].	
Poly(ADP-ribosyl)ation	 is	 involved	 in	DNA	base-excision	
repair	 (BER)	 that	allows	 to	protect	 the	proliferating	cells	 from	
certain	types	of	DNA	damage,	including	those	related	to	oxidative	
stress,	 i.	e.	abasic	sites,	and	DNA	single-strand	breaks	 that	are	
directly	or	indirectly	generated	by	reactive	oxygen	species	(ROS)	
[13,	14].	
Recently,	 Piskunova	 et	 al.	 [15]	 revealed	 that	 deficiency	
in	 poly(ADP-ribose)	 polymerase-1	 accelerates	 aging	 and	
spontaneous	carcinogenesis	in	mice.	
In	 this	 study	 the	 authors	 discovered	 that	 PARP-1	 null	
homozygous	 mice	 exhibit	 a	 reduction	 of	 life-span	 along	 with	
a	 significant	 increase	 of	 aging	 population	 rate	 and	 shortening	
of	 mortality	 rate	 doubling	 time.	 Although	 the	 incidence	 of	
spontaneous	tumors	in	this	population	was	similar	to	wild	type	
animals,	 the	 malignant	 neoplasms	 were	 significantly	 more	
frequent	in	mice	devoid	of	PARP-1	gene.
It	has	also	been	shown	that	human	malignant	tumors	display	
higher	poly(ADP-ribosyl)ation,	PARP-1	activity	or	PARP	gene	
expression	 than	was	 revealed	 in	neighboring	cancer-free	 tissue	
[16,	17,	18,	19,	20].	Brustmann	[21]	using	immunocytochemistry	
showed	 that	 PARP-1	 expression	 in	 serous	 ovarian	 cancers	 is	
not	 only	 higher	 than	 in	 borderline	malignancy	but	 it	 increases	
correspondingly	 to	neoplasm	advancement	classified	according	
to	 FIGO.	He	 also	 showed	 that	 benign	 ovarian	 tumors	 did	 not	
display	enzyme	protein	expression.	As	mentioned	by	Brustmann,	
the	 mechanism	 of	 PARP-1	 up-regulation	 in	 human	 cancer	 is	
not fully understood since the enzyme, which is currently also 
known	as	‘the	guardian	angel’,	is	believed	to	be	a	suppressor	of	
tumorigenesis	due	to	its	ability	to	protect	the	genome	[22,	23].
To	 the	 best	 of	 our	 knowledge	 there	 have	 been	 only	 two	
studies	 concerning	 PARP-1	 expression	 in	 endometrial	 normal	
and	cancerous	tissues	[23,	24],	both	of	them	limited	to	the	topic	
of	 immunohistochemical	 PARP	 density.	 There	 has	 been	 no	
information	on	enzyme	activity	in	endometrial	tissues,	including	
uterine	cancer	which	is	the	most	common	malignant	tumor	of	the	
female	genital	organs	in	developed	countries	[25,	26].	
In	the	paper	the	authors	present	PARP-1	activity	in	normal	
and	 cancerous	 human	 endometrial	 samples.	 Additionally,	 the	
authors	tried	to	discover	the	relationship	of	the	enzyme	activity	
with	 abasic	 sites	 level,	 since	 this	 oxidative	 stress	 marker	 is	
recognized	during	BER	as	a	single	strand	 lesion	and	 thus	may	
activate	PARP-1	[27].
 Streszczenie
Cel pracy: badanie aktywności polimerazy poly(ADP-ryboza) (PARP-1) w prawidłowej i w nowotworowo zmienio-
nej błonie śluzowej macicy w relacji do liczby miejsc apurynowych/apirymidynowych (AP), uznanych za aktywatora 
enzymu.
Materiał i metody: badania wykonano w utkaniu 15 gruczolakoraków endometrium oraz 47 fragmentach prawid-
łowej błony śluzowej macicy. Aktywność PARP oznaczano przy użyciu Universal Colorimetric PARP Assay Kit (Tre-
vigen) i przeliczano na miligram białka. Liczbę miejsc AP kwantyfikowano w 105 par zasad wykorzystując Oxidative 
DNA Damage Kit Quantitative (Kamiya). Aktywność polimerazy w utkaniu nowotworowym analizowano w relacji do 
niektórych histologiczno-klinicznych cech guzów gruczołowych.
Wyniki i wnioski: 
1.  nie stwierdzono różnic aktywności PARP-1 w relacji do typu histologicznego nowotworowo niezmienionej błony 
 śluzowej macicy; 
2.  średnia aktywność enzymu była niższa w utkaniu gruczolakoraków niż w endometrium nienowotworowym 
 (2,89±0,55 vs. 6,39±0,06; p<0,005); 
3. średnia aktywność PARP-1 w utkaniu nowotworów wyżej zróżnicowanych histologicznie była wyższa niż 
 odnotowano w guzach G3 i niższa w gruczolakorakach wykazujących głęboką penetrację błony mięśniowej 
 trzonu macicy; 
4.  w utkaniu guzów gruczołowych endometrium nie stwierdzono relacji między aktywnością PARP-1 a liczbą 
 miejsc AP.
 Słowa kluczowe: aktywność PARP-1 / endometrium u kobiet / 
     / gruczolakorak błony śluzowej macicy / 
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Material and methods
The	activity	of	PARP-1	and	AP	 sites	 level	 estimates	were	
done	in	15	specimens	of	sporadic	endometrial	adenocarcinomas	
and	 47	 non-cancerous	 endometrial	 samples,	 obtained	 from	
women	who	 had	 undergone	 surgery	 of	 internal	 genital	 organs	
at	 the	 II	 Department	 of	Gynecology	 of	Medical	University	 in	
Lublin,	Poland.	A	small	amount	of	tissue	material	received	for	our	
investigations	due	to	necessity	of	performing	the	postoperative	
microscopic	evaluation	did	not	permit	estimating	both	PARP-1	
activity	and	AP	sites	 in	every	collected	 tissue	specimen.	Thus,	
the	 number	 of	 cases	 taken	 for	 correlation	 analyses	 was	 lower	
than	 the	 total	 number	 of	 presented	 measurements.	 Informed	
consent	was	obtained	from	every	woman	who	was	enrolled	into	
the	 study.	 Mean	 (±SEM)	 age	 of	 cancer	 affected	 women	 was	
58.8±2.1	(range	42-79	years)	whereas	cancer-free	endometrium	
was	 excised	 from	wombs	 of	 younger	 patients	 removed	 during	
surgery	(49.6±1.2;	range	31-76	years).	Pathological	assessment	
of	the	neoplasms	was	performed	according	to	the	WHO	staging	
system	 [28].	There	were	 three	 (20%)	well-differentiated	 (G1),	
10	 (67%)	 moderately-differentiated	 (G2)	 and	 two	 (13%)	
poorly-differentiated	 (G3)	 tumors.	 2/3	 cases	 showed	 less	 than	
50%	infiltration	of	the	uterine	wall	thickness,	whereas	5	(33%)	
neoplasms	revealed	invasion	above	half	of	the	myometrium.	Ten	
samples	of	endometrial	adenocarcinomas	were	categorized	into	
stage	IB,	four	into	stage	IC	and	one	into	stage	IIB	based	on	FIGO	
staging	scale	[29].
Non-cancerous	endometrium	according	to	commonly	known	
histological	 criteria	 was	 divided	 into:	 proliferative	 (n=19),	
secretory	(n=12),	atrophic	(n=12)	and	hyperplastic	(n=4).
After	hysterectomy,	the	uterine	corpus	was	gently	cut	from	
the	fundus	toward	internal	os	of	the	cervical	canal	to	avoid	any	
contamination	 of	 the	 uterine	 cavity	 with	 endocervical	 cells.	
Opened	uterine	cavity	was	 then	washed	 twice	with	cold	 (4°C)	
physiological	 saline	 solution	 to	 remove	 blood	 clots	 or	 uterine	
discharge.	The	 tissue	material	was	 then	 immediately	 collected	
into	sterile	Eppendorf	tubes	under	binocular	magnification	(5x)	
using	 punch	 biopsy	 forceps.	All	 tissue	 samples	 were	 quickly	
frozen	and	stored	in	liquid	nitrogen.	The	Universal	Colorimetric	
PARP	Assay	 Kit	 (Trevigen)	 containing	 a	 histone-coated	 plate	
was	 used	 to	 estimate	 the	 PARP-1	 activity	 in	 units/mg	 protein	
[30].	 The	 amount	 of	AP	 sites	 was	 estimated	 using	 Oxidative	
DNA	Damage	Kit	Quantitative	(Kamiya	Biomedical	Company)	
as	described	earlier	[31].
Statistical	calculations	were	done		using	StatSoft,	Inc.	(2009)	
STATISTICA	(data	analysis	software	system),	version	9.0.	www.
statsoft.com.
U Mann-Whitney test was used to check statistical 
differences	 and	 correlation	 analyses	 were	 performed	 using	
Spearman’s	 rank	correlation	coefficient.	All	data	are	expressed	
as	the	means	±SEM.	
Results
In	 non-cancerous	 endometrium	 (n=43)	 the	 mean	 PARP-1	
activity	was	6.39±0.06U/mg	protein	(range,	0.57-16.77;	median	
5.3).	There	was	a	negative	correlation	between	enzyme	activity	
and	 age	of	women,	 however	 it	was	not	 statistically	 significant	
(R=	-0.71,	p=0.48).	In	the	proliferative	endometrium	(n=17)	the	
mean	 PARP-1	 activity	 was	 7.11±0.99	 (range,	 0.57-13.0)	 and	
in	this	group	the	protein	activity	was	not	related	to	patient	age	
 
Fig. 1. The mean±SEM PARP-1 activity in proliferative (EP), secretory (ES), 
atrophic (EA) and hyperplastic (EH) endometrium. 
 
Fig. 2. The mean±SEM PARP-1 activity in non-cancerous (EN) and neoplastic 
(EC) endometrium, *p<0.005.
 
Fig. 3. The mean±SEM PARP-1 activity in endometrial carcinomas according to 
WHO, *p<0.04; **p<0.026.
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(R=	-0.07,	p=0.99).	In	secretory	endometrium	the	mean	PARP-
1	 activity	 (n=12)	was	 roughly	 the	 same	 as	 in	 the	 proliferative	
one	(6.59±1.29;	range,	1.58-15.06,	median	4.73).	There	was	no	
relationship	between	enzyme	activity	and	age	in	this	investigated	
group	 (R=0.03,	 p=0.92).	 Hyperplastic	 endometrium	 (n=4)	
displayed	 the	 mean	 PARP-1	 activity	 quite	 similar	 to	 those	
recognized	in	proliferative	tissue	(7.04±3.39,	range	1.08-16.77).	
Additionally,	 there	 was	 strong	 but	 non-significant	 negative	
correlation	 between	 polymerase	 activity	 and	 the	 age	 of	 the	
women	(R=	-0.63,	p=0.37).
Lowest	 mean	 PARP-1	 activity	 (4.71±1.16)	 was	 found	 in	
atrophic	endometrium	specimens	(n=10).	Similarly	to	proliferative	
tissue, there	were	 interindividual	 substantial	 differences	 in	 the	
enzyme	activity	(0.64-11.71;	median	3.9).	(Fig.	1.).	
The	 activity	 of	 poly(ADP-ribose)	 polymerase	 in	
adenocarcinomatous	endometrium	samples	(n=15)	was	between	
0.61	 to	 6.58	 U	 per	 milligram	 of	 protein.	 The	 mean	 enzyme	
activity	in	those	tissues	(2.89±0.55)	was	statistically	lower	than	
in	the	cancer-free	endometrium	(p<0.005).	(Fig.	2.).
In	 well-differentiated	 endometrial	 adenocarcinomas	 the	
mean	PARP-1	 activity	 (1.77±1.65)	was	 almost	 two	 fold	 lower	
than	in	G2	(3.64±2.13)	and	two	fold	higher	than	in	G3	cancers	
(0.78±0.2).	 However,	 these	 differences	 were	 not	 statistically	
significant.
PARP-1	 activity	 in	 G3	 endometrial	 neoplasms	 was	
significantly	lower	than	in	moderately-differentiated	tumors	(p<	
0.04)	or	those	recognized	in	cancers	displaying	lower	histological	
dedifferentiation	(G1+G2)	(3.14±0.57;	p<0.026).	(Fig.	3.).
In	 tumors	 invading	myometrium	 for	more	 than	 half	 of	 its	
thickness	the	mean	polymerase	activity	was	significantly	lower	
than	 in	neoplasms	displaying	 lower	 local	 invasiveness	 activity	
(1.38±0.58	vs	3.63±0.67;	p<0.013).	(Fig.	4.).
The	amount	of	AP	sites	expressed	per	100000	bp	of	genomic	
DNA	in	cancer-free	endometrium	was	included	between	13.8	to	
71.9	(mean	33.1±2.04;	median	29.7).	There	was	no	correlation	
between	amount	of	 this	oxidative	 stress	molecular	marker	 and	
poly(ADP-ribose)	 polymerase-1	 activity	 (R=-0.04;	 p=0.81).	
(Fig.	5.).
The	 highest	 mean	 AP	 sites	 was	 recognized	 in	 atrophic	
endometrium	 samples	 DNA	 (40.03±4.48).	 It	 was	 statistically	
higher	 (p<0.04)	 than	 in	 secretory	 endometrial	 tissue	
(25.51±2.06),	slightly	exceeding	the	mean	values	in	proliferative	
and	 hyperplastic	 endometrium	 (34.73±3.33	 vs	 33.05±4.33,	
respectively).	 There	 was	 no	 correlation	 between	 abasic	 sites	
quantity	and	PARP-1	activity	in	our	investigation,	irrespectively	
of	the	histological	type	of	cancer-free	endometrium.
In	uterine	adenocarcinomas	the	mean	AP	sites	(37.26±2.31)	
was	non-significantly	higher	than	in	non-cancerous	endometrium	
(p<0.09).	The	quantity	of	this	stress	oxidative	marker	in	neoplasms	
was	 inversely	correlated	with	PARP-1	activity,	however	 it	was	
not	statistically	significant	(R=	-0.48,	p<0.086).	(Fig.	6.).
Discussion
To	the	best	of	our	knowledge	the	present	study	has	been	the	
first	attempt	at	describing	PARP-1	activity	in	human	cancerous	
and	 cancer-free	 endometrial	 tissue.	 Information	 about	 this	
enzyme	in	endometrial	tissue	is	scarce	and	covers	only	PARP-1	
immunohistochemical	expression	[23,	24].	Thus,	we	believe	our	
observations	may	constitute	a	starting	point	for	further	research.	
 
Fig. 4. The mean±SEM PARP-1 activity in uterine adenocarcinomas according to 
the depth of myometrial invasion, *p<0,013.. 
 
Fig. 5. Relationship between AP sites quantity and PARP-1 activity in non-
cancerous human endometrium.
 
Fig. 6. Relationship between AP sites quantity and PARP-1 activity in human 
uterine adenocarcinomas.
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Since	 estrogens	 are	 believed	 to	 stimulate	 PARP	 activity	 and	
proliferation,	we	expected	to	observe	highest	polymerase	activity	
in	 proliferative	 and	 hyperplastic	 endometrial	 tissues	 as	 they	
reflect	elevated	serum	estradiol	 levels	 [32,	33].	 Indeed,	similar	
mean	values	of	PARP-1	activity	in	those endometrial	samples	that	
displayed	increased	proliferative	potential	were	the	highest,	what	
could	support	the	theory	that	estrogenic	stimulation	leads	to	the	
activation	of	poly(ADP-ribose)	polymerase	[24].	Mean	PARP-1	
activity,	 slightly	 lower	 than	 in	 proliferative	 endometrium,	was	
noted	 in	 secretory	 endometrium,	 possibly	 due	 to	 progesterone	
influence	on	PARP	activation	machinery.	Although	 this	 steroid	
increased	 enzyme	 activity	 in	 sheep	 ovarian	 surface	 epithelial	
cells	culture	correspondingly	to	the	applied	dose,	in	spayed	rats	it	
blocked	estrone-stimulated	PARP	activity	[33,34].	In	the	secretory	
phase	of	a	woman’s	menstrual	cycle,	that	might	be	characterized	
by	 secretory	 endometrium,	 relatively	 high	 estradiol	 level	 and	
increasing	blood	progesterone	concentration	which	dramatically	
drops	down	just	before	menstruation,	are	still	observed,	similarly	
to	 the	proliferative	phase.	Thus,	 according	 to	 the	experimental	
data	of	Cummings,	the	secretory	endometrium	PARP-1	activity	
ought	to	be	lower	than	during	the	proliferative	phase	since	blood	
progesterone	is	very	low	at	that	time	[33].	
Assuming	 that	 hormonal	 regulation	 of	 PARP	 activity	 is	 a	
fact,	 it	 came	 as	 no	 surprise	 that	 the	 lowest	 poly(ADP-ribose)	
polymerase	activity	was	recognized	in	the	atrophic	endometrium.	
Such	endometrial	tissue	becomes	atrophic	after	the	menopause	as	
a	result	of	ovarian	insufficiency.	At	that	time	of	a	woman’s	life,	
estrone	becomes	the	predominant	estrogen.	Estrone	is	a	weaker	
estrogenic	compound	comparing	 to	 the	previously	(i.	e.	during	
the	reproductive	period)	secreted	estradiol,	which	is	believed	to	
be	the	most	biologically	potent	human	estrogen	[35].	Thus,	the	
decreased	 enzyme	activity	 could	not	 only	be	 the	 result	 of	 low	
blood	estrogens,	but	might	also	depend	on	the	kind	of	estrogenic	
compound	that	dominates	the	climacteric	blood	of	women.
Our	results	of	PARP-1	activity	in	cancer-free	endometrium	
correspond	 to	 those	 	 published	 by	Ghabreau	 et	 al.	 concerning	
nuclear	enzyme	immunoreactivity	[24].	They	revealed	a	significant	
decrease	of	PARP-1	expression	toward	the	end	of	the	secretory	
phase.	Additionally,	the	highest	immunostaining	of	PARP-1	was	
noted	in	the	late	proliferative	phase,	just	before	ovulation,	when	
blood	estradiol	increases	to	its	maximal	concentration.	
Brustmann	 using	 the	 same	 antibody	 as	 Ghabreau	 team,	
showed	low	immunoreactivity	of	PARP	in	normal	proliferative	
endometrium,	 but	 individual	 immunoscores	 were	 lowest	 in	
secretory	 endometrial	 [23].	 Those	 results,	 together	 with	 our	
findings,	 strongly	 support	 the	 experimental	 data	 that	 estrogens	
may	 activate	 poly(ADP-ribose)	 polymerase,	 thus	 potentiating	
poly(ADP	ribosyl)ation.	
We	 are	 also	 deeply	 convinced	 that	 hormonal	 changes	
occurring	 during	 the	 menstrual	 cycle	 are	 at	 least	 partially	
responsible	 for	 interindividual	 substantial	 differences	 in	 the	
activity	of	PARP-1	in	endometrial	tissue.	They	also	could	depend	
on	endometrial	 tissue	heterogeneity,	since	in	our	investigations	
we	 collected	 specimens	 using	 punch	 biopsy	 technique	 instead	
of	tissue	microdissection.	However,	Liotta	and	Petricoin	believe	
that	the	most	accurate	picture	of	the	in	vivo	state	is	reflected	only	
by	 the	 analysis	 of	 cells	 in	 their	 tissue	 environment,	 as	 tissues	
are	‘complicated	three-dimensional	structures	that	are	composed	
of	 large	 numbers	 of	 interacting	 cell	 populations’	 [36].	 Indeed,	
Cooke	 et	 al.	 demonstrated	 by	 means	 of	 tissue	 recombination	
experiments	that	estradiol	induction	of	mouse	uterine	epithelial	
proliferation	appears	to	be	a	paracrine	event	mediated	by	stromal	
estrogen	receptors	[37].
The	present	 results	 show	 that	PARP-1	 activity	 is	 lower	 in	
estrogen-responsible	uterine	adenocarcinomas	than	in	cancer-free	
endometrium.	 In	contrast,	Singh	 revealed	 that	PARP-1	activity	
was	higher	in	ovarian	cancers	that	are	suspected	to	be	estrogen-
dependent	tumors	than	in	surrounding	disease-free	tissue	[19,38].	
In	breast	cancers,	other	steroid-dependent	neoplasms,	there	was	
higher	 PARP	 expression	 than	 in	 the	 control	 tissue	 specimens	
[20].	
We	suspect	that,	irrespectively	of	the	underlying	mechanisms,	
a	decline	in	PARP-1	activity	should	be	considered	as	a	loss	of	the	
ability	to	defend	against	advancement	of	neoplastic	progression.	
This	view	could	be	supported	by	the	previously	cited	results	of	
Piskunova	et	al.	of	animal	experimental	study,	and	by	our	own	
findings,	which	clearly	demonstrate	that	more	advanced	tumors	
demonstrate	 lower	PARP-1	activity	 [15].	However,	Brustmann	
found	 an	 increase	 of	 immunostaining	 for	PARP	corresponding	
to	 FIGO	 stage	 in	 serous	 ovarian	 carcinomas	 in	 women	 [21].	
Moreover,	Katsuhiko	et	al.	were	able	to	reveal	that	in	colorectal	
early	 stage	 tumors PARP-1	 overexpression	 was	 significantly	
correlated	with	tumor	size	and	histopathology	[39].
On	 the	 other	 hand,	 we	 ought	 to	 stress	 that	 our	 results	
of	 PARP-1	 activity	 in	 uterine	 adenocarcinomas,	 categorized	
according	 to	 WHO,	 are	 roughly	 consistent	 with	 polymerase	
immunoexpression	 demonstrated	 in	 such	 tumors	 by	 Ghabreau	
team	 [24].	 However,	 in	 Brustmann’s	 study	 there	 were	 no	
differences	 in	 PARP-1	 immunoreactivity	 in	 combined	G1	 and	
G2	 uterine	 tumors	 group	 in	 relation	 to	 the	most	 histologically	
dedifferentiated	neoplasms,	 e.	 g.	G3	 [23].	Additionally,	 he	 did	
not	reveal	any	convincing	correlation	between	poly(ADP-ribose)	
polymerase	 expression	 and	 clinicopathological	 variables	 in	
endometrial adenocarcinomas.
Our	 investigations	 of	 PARP-1	 activity	 and	 the	 amount	 of	
abasic	sites	in	non-cancerous	and	neoplastic	endometrium	do	not	
allow	us	to	draw	firm	conclusions	about	the	connection	between	
those	parameters.	However,	 in	 both	 cancer-free	 and	neoplastic	
endometrium	the	highest	values	of	AP	sites	content	were	associated	
with	 lower	 polymerase	 activity.	 Those	 observations,	 along	
with	the	highest	abasic	sites	 level	 in	 the	atrophic	endometrium	
displaying	 lowest	mean	 PARP-1	 activity	 in	 cancer-free	 tissue,	
and	with	the	occurrence	of	a	non-significant	for	the	purpose	of	
study	correlation	between	poly(ADP-ribose)	polymerase	activity	
and	AP	 sites	 level	 in	 cancer-negative	 specimens,	 support	 the	
view	that	PARP-1	can	regulate	 the	severity	of	oxidative	stress,	
thus	playing	an	active	role	in	endometrial	cancer,	also	in	human	
endometrial tissue. 
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